Related Experiment Video
Updated: Mar 27, 2026
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
Ablation of pulmonary oligometastasis in advanced hepatocellular carcinoma treated with Lenvatinib: a retrospective
Ye Li1, Yigong Ren1, Hui Li2
1Department of Interventional Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Background:
In patients with hepatocellular carcinoma (HCC) and pulmonary oligometastasis (PO), the therapeutic effects of metastases ablation remain unclear.
Objective:
This study aimed to compare the efficacy of metastases ablation combined with Lenvatinib (Ablation + Len) with that of Lenvatinib alone (Len) in patients with HCC and PO.
Design:
A multicenter retrospective study.
Methods:
This study included 202 patients in the Len group and 182 patients in the Ablation + Len group. Propensity score matching and inverse probability treatment weighting analyses were used to balance baseline variables between the two groups. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was overall survival (OS).
Results:
The median PFS time was 11.0 ± 0.3 and 14.1 ± 0.5 months in the Len and Ablation + Len groups, respectively. The PFS (hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.49-0.80, p < 0.001) and OS (HR, 0.60; 95% CI, 0.42-0.86; p = 0.006) times were significantly longer in the Ablation + Len group than in the Len group. The OS (HR, 0.62; 95% CI, 0.37-1.03; p = 0.071) and PFS (HR, 0.77; 95% CI, 0.51-1.17; p = 0.230) did not differ among patients with hepatic tumors in stable disease (SD) status. However, among patients in partial response, the OS (HR, 0.57; 95% CI, 0.34-0.95; p = 0.030) and PFS (HR, 0.50; 95% CI, 0.37-0.69; p < 0.001) were significantly different between the two groups.
Conclusion:
Ablation of PO combined with Lenvatinib resulted in longer PFS and OS than treatment with Lenvatinib alone. However, patients did not derive survival benefits from the ablation of metastases when the hepatic tumors were in SD status.
